聚乙二醇化脂质体阿霉素与卡铂治疗晚期复发性卵巢癌：一项法国国立癌症中心妇科肿瘤组（GINECO）的II期试验
Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
作者信息
Weber Béatrice, Lortholary Alain, Mayer Françoise, Bourgeois Hugues, Orfeuvre Hubert, Combe Martin, Platini Christian, Cretin Jacques, Fric Danièle, Paraiso Désiré, Pujade-Lauraine Eric
机构信息
Department of Medical Oncology: Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Université Paris Descartes (AP-HP), Paris, France.
出版信息
Anticancer Res. 2009 Oct;29(10):4195-200.
BACKGROUND
The GINECO group previously demonstrated that pegylated liposomal doxorubicin (PLD)-carboplatin combination was an effective and well-tolerated treatment for advanced ovarian cancer (AOC) patients in late relapse. The purpose of the present analysis was to confirm these results in a prospective cohort of late-relapsing AOC patients.
PATIENTS AND METHODS
Eighty-one consecutive patients received PLD 30 mg/m(2), followed by carboplatin (area under the curve) 5 mg min/ml, every 28 days for 6 courses or until progression.
RESULTS
The objective response (OR) rate was 65.4%. The median progression-free survival (PFS) and overall survival (OS) were 13.6 months and 38.9 months, respectively. Haematological toxicities were more common than non-haematological toxicities. Non-hematologic adverse reactions were moderate and grade 3 palmar-plantar erythrodysesthesia was limited to one patient. No cardiotoxicity was observed and no toxic death occurred.
CONCLUSION
These data support the clinical efficacy and tolerability of PLD in combination with carboplatin as second-line therapy for AOC patients in late relapse.
背景
GINECO研究组之前证实，聚乙二醇化脂质体阿霉素（PLD）-卡铂联合用药对晚期复发的晚期卵巢癌（AOC）患者是一种有效且耐受性良好的治疗方法。本分析的目的是在晚期复发的AOC患者前瞻性队列中证实这些结果。
患者和方法
81例连续患者接受PLD 30 mg/m²，随后接受卡铂（曲线下面积）5 mg·min/ml，每28天一次，共6个疗程或直至病情进展。
结果
客观缓解（OR）率为65.4%。中位无进展生存期（PFS）和总生存期（OS）分别为13.6个月和38.9个月。血液学毒性比非血液学毒性更常见。非血液学不良反应为中度，3级手足红斑感觉异常仅限于1例患者。未观察到心脏毒性，也未发生毒性死亡。
结论
这些数据支持PLD联合卡铂作为晚期复发AOC患者二线治疗的临床疗效和耐受性。
Zotero 插件